Lemakalim

Drug Profile

Lemakalim

Alternative Names: BRL 38227; Levanex; Levcromakalim; Levro-cromakalim

Latest Information Update: 18 Jan 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Meiji Seika Kaisha
  • Class Antiasthmatics; Antihypertensives; Benzopyrans; Bronchodilators; Small molecules
  • Mechanism of Action KATP channel stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Arrhythmias; Asthma; Hypertension; Ischaemic heart disorders

Most Recent Events

  • 15 Oct 2002 No development reported - Preregistration for Hypertension in Japan (PO)
  • 23 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
  • 16 Dec 1999 Profile reviewed, but no significant modifications made
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top